Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
34 results about "Seasonal Affective Disorders" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Systems and articles for enhancing wellness associated with habitable environments
ActiveUS20170068782A1Good environmental characteristicsReduce and ameliorate adverse effectPhysical therapies and activitiesMechanical apparatusSeasonal Affective DisordersResidence
Owner:DELOS LIVING LLC
Methods for enhancing wellness associated with habitable environments
ActiveUS20170053068A1Improve the environmentGood environmental characteristicsPhysical therapies and activitiesMechanical apparatusSeasonal Affective DisordersResidence
Environmental characteristics of habitable environments (e.g., hotel or motel rooms, spas, resorts, cruise boat cabins, offices, hospitals and / or homes, apartments or residences) are controlled to eliminate, reduce or ameliorate adverse or harmful aspects and introduce, increase or enhance beneficial aspects in order to improve a “wellness” or sense of “wellbeing” provided via the environments. Control of intensity and wavelength distribution of passive and active Illumination addresses various issues, symptoms or syndromes, for instance to maintain a circadian rhythm or cycle, adjust for “jet lag” or season affective disorder, etc. Air quality and attributes are controlled. Scent(s) may be dispersed. Noise is reduced and sounds (e.g., masking, music, natural) may be provided. Environmental and biometric feedback is provided. Experimentation and machine learning are used to improve health outcomes and wellness standards.
Owner:DELOS LIVING LLC
Artificial light apparatus and its use for influencing a condition in a subject
InactiveUS20100217358A1Inhibition effectMedical devicesLight therapySeasonal Affective DisordersCircadian rhythm
The present invention relates to an artificial light system for modulating circadian rhythms, increasing vigilance and influencing light-associated psychological conditions such as seasonal affective disorder. The system of the invention comprises a source of a green and / or red light and a source of blue light both light sources being controlled by a computer to provide predetermined light conditions. More specifically, the computer is programmed to provide pulses of blue light and continuous or pulsed red light, to enhance the efficacy of blue light, reduce blue-light hazard and avoid stroboscopic effect.
Owner:UNIV LAVAL
Portable light delivery apparatus and methods
InactiveUS6955684B2Improve wear resistanceAssist in portabilityLight therapySeasonal Affective DisordersLight delivery
A portable light delivery device for delivering light to the blood supply of a human body through a nonocular area of skin on the body includes an attachment member, a portable light delivery unit connected to the attachment member and a portable power supply. The portable light delivery unit provides one or more wavelengths of light within a specifically determined range of intensity and a specifically determined angle of illumination. A portable control unit may be included on the light delivery device for selectively controlling the light delivery unit. A programming device associated with the control unit selectively changes the programming of the controller. The light delivery device is portably secured to a region of the body having a substantial amount of blood vessels near the surface thereof to deliver light to the blood supply of the body for treating mood disorders, seasonal affective disorder and disorders involving circadian rhythm and sleep.
Owner:PHILIPS ELECTRONICS NORTH AMERICA
Method and device for monitoring and treatment of seasonal affective disorder
ActiveUS20140277291A1Effective treatmentPositive experienceSensorsLight therapyLight therapySeasonal Affective Disorders
This invention provides for an energized biomedical ophthalmic device and associated method of measuring changes in biomarkers contained in tear film to generate data related to a light therapy regimen used to treat symptoms associated with seasonal affective disorder. In some embodiments, the energized biomedical ophthalmic device can include an energized contact lens with a light source in communication with a processor controlling said light source according to the light therapy regimen. The light therapy regimen may be generated or modified by the processor from the measured changes and sometimes from user's preferences, and / or additional measurements, including for example, light exposure and / or circadian rhythm of the user.
Owner:JOHNSON & JOHNSON VISION CARE INC
Mobile device case with ultraviolet light sanitizer and light therapy
A protective case for a mobile electronic device is provided. The case includes at least one light emitting diode that emits electromagnetic radiation in the range of UV-C light for sanitizing contaminated surfaces. The case also includes additional LEDs that emit light at wavelengths known to have a therapeutic effect such as a blue light for treating seasonal affective disorder. The LEDs are provided in a separate encasement that is detachable from the protective cover configured to receive and protect the mobile electronic device. A short-range wireless receiver is included to communicate with an application installed on the mobile electronic device for controlling the activation, intensity, duration and mode of the LEDs including predetermined treatment or sanitization protocols.
Owner:ETS TECH LLC
Mobile device case with ultraviolet light sanitizer and light therapy
ActiveUS9925390B2Light therapyX-ray tube with very high currentSeasonal Affective DisordersUv disinfection
Owner:ETS TECH LLC
Method of treating depression with delta receptor agonist compounds
InactiveUS7030124B2Organic active ingredientsNervous disorderSeasonal Affective DisordersClinical psychology
Methods for treatment of depression or other affective mood disorders, such as bipolar manic depression or seasonal affective disorder, are disclosed by administration to a subject suffering or susceptible to same, of therapeutically effective diarylpiperazine compounds as herein described.
Owner:ENTA HLDG +1
Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (+)-bupropion
InactiveUS20010011103A1Reduce adverse effectsEffective treatmentOrganic active ingredientsBiocideReflexSeasonal Affective Disorders
Methods and compositions are disclosed utilizing the optically pure (+)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.
Owner:SEPACOR INC
Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (+)-bupropion
InactiveUS6495605B2Reduce adverse effectsEffective treatmentBiocideOrganic active ingredientsReflexSeasonal Affective Disorders
Methods and compositions are disclosed utilizing the optically pure (+)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.
Owner:SEPACOR INC
Method and device for monitoring and treatment of seasonal affective disorder
ActiveUS9289623B2Effective treatmentPositive experienceSensorsPsychotechnic devicesLight therapySeasonal Affective Disorders
This invention provides for an energized biomedical ophthalmic device and associated method of measuring changes in biomarkers contained in tear film to generate data related to a light therapy regimen used to treat symptoms associated with seasonal affective disorder. In some embodiments, the energized biomedical ophthalmic device can include an energized contact lens with a light source in communication with a processor controlling said light source according to the light therapy regimen. The light therapy regimen may be generated or modified by the processor from the measured changes and sometimes from user's preferences, and / or additional measurements, including for example, light exposure and / or circadian rhythm of the user.
Owner:JOHNSON & JOHNSON VISION CARE INC
Bombesin receptor antagonists
Bombesin receptor antagonists are provided which are compounds of formula (I) or pharmaceutically acceptable salts thereof: wherein j, k, l, m, n, q, r, Ar, Ar<1>, R<1>, R<2>, R<3>, R<4>, R<5>, R<6 >and X are as defined in the description. The compounds of the invention have an affinity for the BB1 receptor and some of them also have affinity for the BB2 receptor. Accordingly they may be useful for the diagnosis, prevention, or treatment of male and female sexual dysfunction. They can also be used in the diagnosis, prevention or treatment of anxiety and panic disorders, social phobia, depression, psychoses, sleeping disorders, memory impairment, pulmonary hypertension, lung repair and lung development disorders, cancer including prostate cancer and pancreatic cancer, hepatic porphyria, gastrointestinal secretory disturbances, gastrointestinal disorders including colitis, Crohn's disease and inflammatory bowel disease, emesis, anorexia, pain, seasonal affective disorders, feeding disorders or pruritus.
Owner:WARNER-LAMBERT CO
High dosage Vitamin D
InactiveUS20090196862A1Useful in treatmentOrganic active ingredientsBiocideHypertension medicationsSeasonal Affective Disorders
A preparation containing vitamin D3 (cholecalciferol), preferably an edible oil, in an amount of 200 IU to 20,000 IU, preferably 1000 IU to 5000 IU, and most preferably about 1500 IU to 3500 IU, with about 2000 IU particularly preferred. Such a preparation is useful in providing adequate nutrition, in the prevention and / or treatment of Seasonal Affective Disorder (SAD), fall prevention, multiple sclerosis, chemoprevention of cancer, accelerated fracture healing, and metabolic syndrome. It acts as an anti-depressant, an anti-hypertensive for renovascular hypertension and high-renin hypertension; and is useful in hyperlipidemia treatment, as well as in the treatment of hypovitaminosis D in the renal failure population. The most important application to the present inventors is in treatment, prevention and also reversal of hypertension in renovascular and high-renin hypertension. The effective amount of vitamin D, based on blood serum content, is equal to or greater than 20 ng / mL, preferably equal to or greater than 40 ng / mL, and most preferably equal to or greater than 50 ng / mL, with no specific upper range, but preferably equal to or less than 200 ng / mL, and more preferably equal to or less than 100 ng / mL.
Owner:DAVIS WILLIAM +1
Drechsleranol derivatives, processes for their preparation and their use
The present invention provides novel drechsleranol compounds of formula (I) which are formed by the microorganism Drechslera australlensis, ST 003360, DSM 14093, or a fungus ST 004112, DSM 14524, during fermentation. A process for their preparation, pharmaceutical compositions containing said drechsleranols their use for the treatment and / or prophylaxis of degenerative neuropathies, such as, Alzheimeu's disease, or psychiatric disorders, such as depression, sleep disturbance or seasonal affective disorder, and their use as chelating agents or antioxidants are also disclosed and claimed.
Owner:SANOFI AVENTIS DEUT GMBH
Combination Therapy with Mecamylamine for the Treatment of Mood Disorders
InactiveUS20080058345A1Good curative effectEffective treatmentBiocideNervous disorderSeasonal Affective DisordersCombined Modality Therapy
A combination therapy for treating mood disorders, including depressive disorders such as major depression, panic disorder, obsessive compulsive disorder, social anxiety disorder, seasonal affective disorder, and premenstrual dysphoria is provided herein. The combination therapy comprises administering an effettive amount of mecamylamine together with at least one agent for treatment of a mood disorder to a patient in need of treatment of the mood disorder. Pharmaceutical formulations, including packaged pharmaceutical formulations, comprising mecamylamine and an additional agent, such as an SSRI, are also provided herein.
Owner:YALE UNIV
Novel pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
PendingUS20200323876A1Organic active ingredientsPharmaceutical delivery mechanismSeasonal Affective DisordersCompulsive disorders
Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, childhood enuresis, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.
Owner:LA PHARMATECH INC
Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-) -bupropion
InactiveUS20040225020A1Reduce adverse effectsEffective treatmentBiocideOrganic active ingredientsReflexSeasonal Affective Disorders
Methods and compositions are disclosed utilizing the optically pure (-)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.
Owner:SEPACOR INC
Method for inhibiting melatonin secretion and illumination device suitable for being applied in light therapy for treating seasonal affective disorder
ActiveUS20210008387A1Suppression problemEasy to moveLight therapySleep inducing/ending devicesLight therapySeasonal Affective Disorders
Disclosures of the present invention describe a method for inhibiting melatonin secretion. In the present invention, an illumination device is particularly configured for emitting an illumination light with a specific wavelength that is in a range between 581 nm and 590 nm, and a variety of experimental data have proved that the illumination light functions as a melatonin secretion inhibitor. Therefore, the illumination device of the present invention is evidenced to be suitable for use in light therapy, so as to treat seasonal affective disorder (SAD) by way of inhibiting melatonin secretion. Briefly speaking, after a SAD patient receives the irradiation of the illumination light having wavelength ranged in 581-590 nm for a treatment course, the SAD patient is eventually leaded to stay in good spirits and a stable condition of emotion, thereby curing the abnormal symptoms of sleepiness and emotional disorder.
Owner:NATIONAL TSING HUA UNIVERSITY
Apparatus and method for influencing a condition in a subject
Owner:UNIV LAVAL
Healthy sun-like rays umbrella
InactiveUS20110232703A1Avoid disadvantagesSimple and inexpensive to manufactureWalking sticksClubsSeasonal Affective DisordersBlue light
A healthy sun-like rays umbrella includes at least one UV blue light emission device and a means for mounting the at least one UV blue light emission device onto at least one stretcher of the umbrella. At least one person using the umbrella will receive the benefits of the at least one UV blue light emission device for a seasonal affective disorder and a more versatile way to increase vitamin D levels.
Owner:OHARA BLANCHE
Method for inhibiting melatonin secretion by light source and lighting device
The invention provides a method for inhibiting melatonin secretion by using a light source. According to the method, a lighting device is specially designed to emit lighting light having a specific wavelength within the wavelength range of 581nm and 590nm, and various experimental data have proved that the lighting light can be used to serve as a melatonin secretion inhibitor. Therefore, the experimental data have proved that the lighting device of the invention is suitable for being used for light therapy for winter depression, thereby treating the seasonal affective disorder (namely the winter depression) by inhibiting the melatonin secretion. Briefly speaking, after a patient suffering from the winter depression receives a treatment course of the light therapy with the lighting light with the wavelength range of 581-590nm, the symptoms of the winter depression, including somnolence, emotional disorder and the like, of the patient suffering from the winter depression can be cured finally due to the fact that the patient has a good mental state and a stable emotional state.
Owner:周卓煇
N-(2-(substituted-naphth-1-yl)ethyl)-substituted amide compounds, and preparation thereof and application thereof
InactiveCN109251151AOrganic active ingredientsNervous disorderSeasonal Affective DisordersEthyl group
The invention relates to N-(2-(substituted-naphth-1-yl)ethyl)-substituted amide compounds, and application of the same as melatonin receptor agonists and 5-HT2c receptor antagonists. Specifically, theinvention relates to the compounds as shown in a formula I which is described in the specification, or pharmaceutically acceptable salts or solvates thereof, or mixtures of the compounds, the salts and the solvates, and pharmaceutical compositions of the compounds, the salts, the solvates or the mixtures. X, R1, R2 in the formula I are as defined in the specification. The compounds as shown in the formula I of the invention can be used as melatonin receptor agonists and 5-HT2c receptor antagonists and is applicable to the preparation of drugs used for treating and / or preventing melatonin system diseases, stress, anxiety, seasonal affective disorders, cardiovascular diseases, digestive diseases, schizophrenia, phobias, depression, major depression, sleep disorders, sleep disturbance, insomnia or fatigue caused by jet lag, weight disorders and other diseases and illnesses.
Owner:BEIJING GREATWAY PHARMA TECH CO LTD
Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them
This invention relates to novel substituted tryptamines and related derivatives, as well as pharmaceutical compositions formulated therefrom. These compounds, compositions and their salts can be used in the manufacture of medicaments for interacting with the melatoninergic system. These compounds and conditions can be used for treating several types of medical conditions, such as central nervous system and psychiatric disorders (sleep disorders, epilepsy and other convulsive disorders, anxiety, neurodegenerative diseases), chronobiological-based disorders (jet lag, delayed sleep syndrome, shift-work, seasonal affective disorder), neoplastic conditions, and conditions associated with senescence.
Owner:NEURIM PHARMA
Pharmaceutical compositions and methods for treatment of psychiatric disorders
ActiveUS11351179B1Nervous disorderHeterocyclic compound active ingredientsSeasonal Affective DisordersCompulsive disorders
Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and folic acid or folate, and / or salts, metabolites, or derivatives thereof are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders or symptoms, such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.
Owner:LA PHARMATECH INC
Herbal formulation for treating chronic fatigue syndrome
InactiveUS20170232050A1Pharmaceutical delivery mechanismGinkgophyta medical ingredientsSeasonal Affective DisordersRaspberry leaf
In one aspect there is provided a liquid herbal composition for relieving some or all of the symptoms of Seasonal Affective Disorder (SAD) and / or Chronic Fatigue Syndrome (CFS) or Myalgic Encephalomyelitis (ME). The liquid herbal composition preferably comprises therapeutically effective amounts of hydroalcoholic extracts of Bilberry, Eyebright, Goldenseal root, Ginkgo leaf, Passion flower and Raspberry leaf. The liquid herbal composition is preferably orally administered on a daily basis.
Owner:ELLERY DAVID
Healthy sun-like rays umbrella
InactiveUS8356611B2Avoid disadvantagesSimple and inexpensive to manufactureWalking sticksClubsSeasonal Affective DisordersBlue light
A healthy sun-like rays umbrella includes at least one UV blue light emission device and a means for mounting the at least one UV blue light emission device onto at least one stretcher of the umbrella. At least one person using the umbrella will receive the benefits of the at least one UV blue light emission device for a seasonal affective disorder and a more versatile way to increase vitamin D levels.
Owner:OHARA BLANCHE
Acrylic water features
InactiveUS20150083819A1Electric lightingLiquid spraying apparatusDiagnostic Radiology ModalitySeasonal Affective Disorders
A illuminated table or desk top water display ornament can be used for everyday enjoyment and appropriate for every season and occasion. The water display ornaments embody a multiplicity of water displays, such as waterfalls, springs, waves, tides, cavitating bubbles, and the like, all combined and cycled in one system. The water display ornaments are simple in construction and maintain an aesthetically pleasing presentation to the viewer. Many options are available as a plug-in or slide-in module. This allows the viewer to change modules if desired to obtain different patterns, flows and sounds as desired. The water display ornaments can be efficacious modalities for attenuating an individual's adverse response to daily, weekly, annual or seasonal circadian cycles, such as seasonal affective disorder. Moreover, the water display ornaments offer life prolonging benefits similar to that attributed, by anecdotal evidence, to the ownership of a pet.
Owner:CIBULSKI ANTHONY ANDREW
Method for curing mild Multiple Sclerosis, memory impairment and Seasonal Affective Disorder
InactiveUS20050106156A1Snake antigen ingredientsAllergen ingredientsSeasonal Affective DisordersApplied kinesiology
A method for curing mild Multiple Sclerosis, memory impairment and Seasonal Affective Disorder. An Applied Kinesiology technique, used to desensitize a patient to allergies, is used to desensitize a patient to myelin and melatonin. Desensitizing the patient to myelin and melatonin cures mild Multiple Sclerosis, memory impairment and Seasonal Affective Disorder.
Owner:LANG HARVEY
Illumination awakening device and method for reducing sleep inertia
ActiveCN106455219AImprove mental stateImprove seasonal affective disorderElectrical apparatusElectroluminescent light sourcesOptical radiationSeasonal Affective Disorders
Owner:GUANGDONG INST OF SEMICON IND TECH
Method for inhibiting melatonin secretion and illumination device suitable for being applied in light therapy for treating seasonal affective disorder
ActiveUS11504545B2Light therapySleep inducing/ending devicesSeasonal Affective DisordersLight therapy
Disclosures of the present invention describe a method for inhibiting melatonin secretion. In the present invention, an illumination device is particularly configured for emitting an illumination light with a specific wavelength that is in a range between 581 nm and 590 nm, and a variety of experimental data have proved that the illumination light functions as a melatonin secretion inhibitor. Therefore, the illumination device of the present invention is evidenced to be suitable for use in light therapy, so as to treat seasonal affective disorder (SAD) by way of inhibiting melatonin secretion. Briefly speaking, after a SAD patient receives the irradiation of the illumination light having wavelength ranged in 581-590 nm for a treatment course, the SAD patient is eventually leaded to stay in good spirits and a stable condition of emotion, thereby curing the abnormal symptoms of sleepiness and emotional disorder.
Owner:NATIONAL TSING HUA UNIVERSITY
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com